Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

By afschroeder • October 7, 2025

Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma. J Cancer. 2025 Aug 11;16(13):3797-3809. doi: 10.7150/jca.117878. PMID: 41049010; PMCID: PMC12490977.

Tags: Checkpoint blockade, Combination immunotherapy, Hematology/Oncology, melanoma, Plozalizumab, Publications, Tovorafenib, Toxicities, vedolizumab

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]

Long-Term Survival After Percutaneous Image-Guided Thermal Ablation of Oligometastatic Renal Cell Carcinoma

Kim DH, Keshavarz P, Tibbe TD, Suh RD, Abtin F, Genshaft SJ, Drakaki A, Shuch BM, Pantuck AJ, Lu DS, Raman SS. Long-Term Survival After[...]

Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without Pembrolizumab in Ultra-Elderly Patients With Advanced Urothelial Carcinoma

Mar N, Cabral MY, Go J, Kaakour D, Dwabe S, Seyedin SN, Drakaki A. Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without[...]